PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Guidelines : Inflammatory bowel disease
Guidelines : Inflammatory bowel disease
Additional Documents
Type
Document
Review Date
Guidelines (Local)
01 December 2021
Guidelines (Local)
01 December 2021
Other Drugs
- Adalimumab
- Azathioprine
- Infliximab
- Mercaptopurine
- Ciclosporin
- Golimumab
- Vedolizumab
- Allopurinol
- Balsalazide sodium
- Prednisolone
- Budesonide
- Tofacitinib
- Methotrexate
- Mesalazine (Systemic)
- Filgotinib
- Sulfasalazine
- Upadacitinib
- Risankizumab
- Olsalazine sodium
Committee Recommendations
Date
Committee Name
Narrative
03 May 2023
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Surrey Heartlands Area Prescribing Committee (APC) agreed an updated Inflammaory Bowel Disease (IBD) pathway for use.